Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Pfizer

Status and phase: Completed; Phase 2

Conditions: Macular Degeneration

Treatments: Drug: pegaptanib sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00239928

A5751015

Details and patient eligibility

About

This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).

Enrollment: 61 patients

Sex: All

Ages: 51+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• After completion of the preceding study (A5751010)

Exclusion criteria

• Serious heart, kidney and/or liver disease
• Diabetic retinopathy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

61 participants in 1 patient group

EYE001

Experimental group

Treatment:

Drug: pegaptanib sodium